ORIC.OQ
Latest Trade
32.58USDChange
-1.90(-5.51%)Volume
59,342Today's Range
-
35.2952 Week Range
-
40.60As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 34.48 |
|---|---|
Open | 35.29 |
Volume | 59,342 |
3M AVG Volume | 6.32 |
Today's High | 35.29 |
Today's Low | 30.63 |
52 Week High | 40.60 |
52 Week Low | 18.76 |
Shares Out (MIL) | 35.59 |
Market Cap (MIL) | 1,227.25 |
Forward P/E | -9.48 |
Dividend (Yield %) | -- |
Oric Pharmaceuticals Provides Corporate Update And Highlights Key 2021 Milestones
Oric Pharmaceuticals Inc Files For Offering Of Up To 4.0 Million Shares Of Common Stock - SEC Filing
Oric Pharmaceuticals Reports Proposed Public Offering Of Common Stock
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.
Industry
Biotechnology & Drugs
Contact Info
240 E. Grand Ave., 2nd Floor
SOUTH SAN FRANCISCO, CA
94080
United States
+1.650.3885600
http://oricpharma.com/Executive Leadership
Richard A. Heyman
Independent Chairman of the Board, Founder
Jacob M. Chacko
Chief Executive Officer, Director
Dominic G. Piscitelli
Chief Financial Officer
Christian V. Kuhlen
General Counsel
Matthew Panuwath
Chief Business Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 5.71 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.